Investors are assessing prescription adoption and commercial execution.
Investors are assessing the September interim results, the SanmirnaAcquisitionand the miRisten clinical programme.
OptiBiotix is in focus because its investment case is moving from research-led development towards commercialisation. Revenue growth, improving gross profit and lower costs are important signals for a small healthcare company seeking to scale internationally. The company remains exposed to the pace at which …
The latest study involved 115 men aged 18 to 59, most with mild to moderate erectile dysfunction. Futura said satisfaction with erection hardness was reported in 82% of encounters, compared with 71% for the original Intense formula, and that the improvement in a standard …
Feedback describes itself as a clinical infrastructure specialist. Its main product, Bleepa, is a clinical communication and digital pathway platform used by NHS organisations to share images and records, manage referrals and move patients through community-based diagnostic and care pathways. The aim is to …
Founded in 2001 as a spin-out from Queen's University Belfast and listed on AIM since December 2017, Fusion Antibodies provides pre-clinical antibody discovery, engineering andSupplyservices to pharmaceutical and biotechnology clients. Its offering includes antibody discovery, affinity maturation and sequence optimisation. According to company information …
Faron is based in Finland and its shares are traded on AIM in London as well as in Helsinki. Its main asset is bexmarilimab, an antibody aimed at the Clever-1 receptor on immune cells, which the company is developing as an immunotherapy. Its most …
Cambridge Cognition Holdings Plc (LSE:COG) is shown up 3.57% for the 8 October 2026 trading reference supplied for this report.
The principal company-specific explanation for this precise intraday fall was not independently established from available reporting. It would be misleading to assign the move to a particular announcement without confirmation. Investor scrutiny is likely to centre on distribution, consumerDemandandRoyaltyreceipts.
The principal company-specific explanation for this precise intraday fall was not independently established from available reporting. It would be misleading to assign the move to a particular announcement without confirmation. Investor scrutiny is likely to centre on ingredient sales, licensing and cash runway.